Clinical trial
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in…
NCT00166725 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00166725 |
|---|---|
| Title | Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients |
| Official title | A Randomized, Open Label, Multicenter Study Evaluating the Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Octreotide LAR |
| Enrollment | 40 |
| Start date | Feb 1, 2004 |
| First posted | Sep 14, 2005 |
| Last update posted | Nov 19, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: